help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwarz, Y. A.
Right arrow Articles by Wilmott, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwarz, Y. A.
Right arrow Articles by Wilmott, R. W.
Am. J. Respir. Cell Mol. Biol., Volume 21, Number 3, September 1999 388-394

Interleukin-1 Receptor Antagonist Inhibits Interleukin-8 Expression in A549 Respiratory Epithelial Cells Infected In Vitro with a Replication-Deficient Recombinant Adenovirus Vector

Yehuda A. Schwarz, Raouf S. Amin, James M. Stark, Bruce C. Trapnell, and Robert W. Wilmott

Division of Pulmonary Medicine, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Division of Pulmonary Medicine, Children's Hospital Medical Center, Cincinnati, Ohio; and Department of Virology, Genetic Therapy, Inc., Gaithersburg, Maryland


    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

In an earlier study, we showed that a recombinant adenovirus vector with deletions in the E1 and E3 regions of the viral genome (AV1LacZ4) induces expression of interleukin (IL)-8 in A549 cells (a human respiratory cell line). IL-8 can be induced through several pathways, including activation by IL-1. We tested the hypothesis that the induction of IL-8 by the AV1LacZ4 adenovirus is accomplished by means of the IL-1/IL-8 activation pathway, which could be blocked by IL-1 receptor antagonist (IRAP). Viral infections of A549 cells were performed at a multiplicity of infection (MOI) of 50 in the presence and absence of IRAP (50 ng/ml). A549 cells were also stimulated with tumor necrosis factor (TNF)-alpha (100 ng/ml), a known stimulant of IL-8, in the presence and absence of IRAP. IL-8 expression was evaluated by Northern blot analysis and enzyme-linked immunosorbent assay. Levels of IL-8 protein and messenger RNA (mRNA) were greater in the infected cells than in the uninfected ones at 24, 48, and 96 h (P < 0.01). Virus-infected cells treated with IRAP expressed 75% less IL-8 mRNA and protein (P < 0.01) than did untreated cells, whereas IRAP pretreatment of TNF-alpha -stimulated cells did not affect IL-8 production. IL-1 production by the virus-infected cells was detectable by concentration of the supernatants and reverse transcription-polymerase chain reaction. We conclude that IL-8 is produced by virus vector-infected cells, partly through IL-1 activation that can be downregulated by IRAP.


    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The most common lethal autosomal recessive disease of the human Caucasian population is cystic fibrosis (CF) (1), with an estimated incidence of 1:2,500. The basic abnormality in CF is a defect of cyclic adenosine monophosphate (cAMP)-regulated chloride secretion by epithelial cells (2). The CF transmembrane conductance regulator (CFTR) gene, located on chromosome 7 at position 7q31, encodes a cAMP-dependent chloride channel in the apical membrane of epithelial cells of the airway and other tissues (5). Following the cloning and sequencing of the CFTR gene in 1989 (2, 6), correction of the basic genetic defect in airway cells of patients with CF by somatic cell gene therapy became feasible. A number of gene delivery systems for this purpose are currently under consideration, including the use of recombinant adenovirus vectors. We evaluated the utilization of a replication-deficient recombinant adenovirus as a viral vector for delivering normal CFTR complementary DNA (cDNA) to airway epithelial cells, with the goal of expressing this gene and correcting the chloride channel defect in the respiratory tract of individuals with CF (7).

A recombinant adenovirus with deletions in the E1 and E3 regions of the viral genome is efficient as a vector in transferring CFTR cDNA into airway epithelial cells in vitro (8). This replication-deficient adenovirus vector is particularly attractive because it has a natural tropism for airway epithelial cells (13). Introduction of this replication-deficient recombinant adenovirus into the lungs of animals resulted in a nonspecific inflammatory response (14). The instillation of a recombinant adenovirus vector containing the Rous sarcoma virus long-terminal-repeat promoter, which drove either a nuclear-targeted gene (AV1LacZ4) or CFTR cDNA (Av1Cf2) in the cotton rat lung, resulted in neutrophil-dominated alveolar and peribronchial cellular infiltration at 3 d after administration (18). The nature of the infiltrate changed from neutrophil-dominated during the first few days to macrophage- and mononuclear cell-dominated by Day 10. Instillation of the same vector into the lungs of macaque monkeys was also associated with a mild to moderate inflammation, the intensity of which was dose-dependent (15). A related recombinant adenovirus vector, utilizing a cytomegalovirus (CMV) promoter and expressing the beta -galactosidase gene (LacZ), induced a moderate inflammation predominantly in the distal lung parenchyma of the baboon (16). Nonhuman primates exposed to an adenovirus vector developed an inflammatory response at 3 d after exposure. Analysis of bronchoalveolar lavage fluid (BALF) for interleukin (IL)-8 showed increased levels of this cytokine in animals that received a high dose of the vector, suggesting that IL-8 might play a role in the vector-induced inflammation seen in these animals (15). We have shown that in vitro cellular transduction of A549 bronchial epithelial cells by Av1LacZ4, at a multiplicity of infection (MOI) of 50 virus particles per cell, resulted in gene delivery to 80 ± 5% of the cell monolayer. Furthermore, by 24 h, IL-8 messenger RNA (mRNA) transcript and neutrophil chemoattractant activity in supernatants from Av1LacZ4-transduced cells were significantly higher than in supernatants from uninfected control cells. IL-8 mRNA and protein levels remained increased for 96 h (19). These findings show that gene delivery to the airway epithelium with the serotype 5 adenovirus (Ad5)-based expression vector results in IL-8 gene activation in these cells, a process that may contribute to understanding of the inflammatory host response to the vector (14, 16, 20).

A549 pulmonary epithelial cells express IL-8 after stimulation with tumor necrosis factor (TNF)-alpha , phorbol myristate acetate (PMA), and IL-1 (20). A549 cells are a valid model for studing the events occurring in airway epithelial cells. CMV and respiratory syncytial virus (RSV) infections are known to induce production of IL-1 in mononuclear cells (21, 22), and RSV infection also induces IL-8 gene activation in epithelial cells (23, 24). We theorized that a potential mechanism for IL-8 induction by virus infection is through primary induction of IL-1, which then induces IL-8. If IL-1 does induce IL-8, the specific IL-1 receptor antagonist (IRAP) could therefore block IL-8 production. The blocking of IL-8 induction by IRAP has been reported by several investigators (25, 26). The present study was done to test the hypothesis that the induction of IL-8 in A549 cells by the adenovirus vector Av1LacZ4 is inhibited by preincubation with human IRAP.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Cell Culture and Experimental Protocol

A549 pulmonary epithelial cells derived from a human alveolar cell carcinoma (American Type Culture Collection, Rockville, MD) were seeded into tissue-culture plates at a density of 5 × 104 cells/cm2 in Dulbecco's modified Eagle's medium (DMEM) (Gibco/BRL, Life Technologies Inc., Grand Island, NY) containing 10% lipopolysaccharide (LPS)-free fetal bovine serum (FBS) (Hyclone, Logan, UT), 100 U/ml penicillin, and 100 mg/ml streptomycin (Sigma Chemical Co., St. Louis, MO). The cells were grown to confluence at 37°C in humidified 95% air/5% CO2. On the day of infection, the cell supernatants were discarded and fresh medium was added. The recombinant adenovirus vector was then added to the monolayer according to the infection protocol. Before the adenovirus vector was added, half of the plates were treated with 50 ng/ml of IRAP. Other A549 cells were stimulated with recombinant human IL-1beta (hIL-1beta ) (Endogen, Boston, MA) in concentrations of 0.2, 2, 20, and 200 pg/ml. For blocking experiments, cell cultures were pretreated with IRAP protein (a kind gift from Synergen, Boulder, CO) at concentrations of 10, 100, 1,000, and 10,000 pg/ml, which were applied 90 min before implementing the adenoviral infection or adding the cytokine stimulant. TNF-alpha at a concentration of 100 U/ml (Endogen) was used as positive control. At 24, 48, and 96 h, cell-free supernatants were collected and cells were trypsinized and counted with a hemocytometer, and the cell viability was determined by trypan blue exclusion. Cells were also harvested for RNA extraction.

Virus Vector Construct

The Av1LacZ4 vector carries a nuclear-targeted LacZ gene. Av1LacZ4 is a first generation, E1a, E3-deleted recombinant adenovirus vector derived from Ad5. The heterologous minigene consists of the Rous sarcoma virus promoter driving expression of the nuclear targeted beta -galactosidase encoding sequence. The construction, purification, and titration of Av1LacZ4 have been described elsewhere (14). The vector was stored in virus dialysis buffer (10 mM Tris-HCl [pH 7.4], 1 mM MgCl2, 10% glycerol) at -70°C until used.

Infection Protocol

Immediately before infection, Av1LacZ4 was thawed and added to the cells in fresh DMEM containing 2% FBS (Hyclone), 100 U/ml penicillin, and 100 mg/ml streptomycin. The vector concentration was calculated on the basis of a desired MOI of 50/cell and a total estimated cell density of 2.5 × 105/cm2 when the monolayer was confluent. This concentration was determined from previous cell-count studies (data not shown). After 90 min of exposure to the virus vector, the FBS concentration in the medium was corrected to 10%.

Enzyme-Linked Immunosorbent Assay

IL-8 and IL-1beta were quantitated with a direct sandwich enzyme-linked immunosorbent assay (ELISA) method (20, 29). Each test sample was assayed in triplicate. A standard titration curve was obtained by making serial dilutions of human recombinant IL-8 protein (R&D Systems, Minneapolis, MN). Light absorption was measured at 450 nm on a THERMOmax microplate reader (Molecular Devices, Inc., Menlo Park, CA). The lower limit of sensitivity for this ELISA was 20 pg/ml.

Concentration of Supernatants

Concentration of supernatants from control cells, cells infected with the virus vector, and cells treated with TNF-alpha was done with Centriprep concentrators (Amicon Inc., Beverly, MA). In essence, 15 ml of supernatant was concentrated in a Centriprep-10 through a three-step centrifugation procedure. The final-to-original concentration ratio was 15:1.

Membrane Preparation

Membrane preparations for control cells, cells infected with the virus vector, and cells treated with TNF-alpha were isolated after 96 h of culture, through a modification of a detergent solubilization method described by Weissman (30).

Northern Blot Analysis

Total RNA was recovered by modification of the acid phenol extraction method of Chomczynski and Sacchi (20, 31). Lysis buffer (4 M guanidinium isothiocyanate, 25 mM sodium citrate [pH 7], 0.1 M beta -mercaptoethanol) was added to each well to extract RNA (0.5 ml/well). Purified RNA was stored at -80°C until further purification was done with Phase Lock Gell II (5 Prime Right-arrow  3 Prime, Inc., Boulder, CO) to optimize the recovery of RNA from the organic extraction according to the manufacturer's directions. RNA was quantified by measuring absorbance at 260 nm after dilution in 10 mM Tris, 0.1 mM ethylenediaminetetraacetic acid (EDTA) (pH 8.0). Aliquots of 15 mg of total RNA were denatured with 6 M glyoxal (40% ethanedial in aqueous solution) (Sigma), dimethylsulfoxide, and 0.1 M sodium phosphate (pH 7.0). The glyoxal solution was deionized (32). Samples containing equal amounts of RNA were fractionated on a 1.2% agarose gel and transferred to nylon membranes (Hybond, Amersham International, Amersham, UK). After crosslinking, the Hybond filters were stained with 1% methylene blue in 0.3 M sodium acetate to assess the integrity of the RNA and to verify the uniformity of loading.

The Hybond filters were then prehybridized for 2 h at 65°C in 5× saline-sodium phosphate-EDTA (SSPE) (1× SSPE = 150 mM NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.4], 5× Denhardt's solution (1× Denhardt's solution is 0.02% bovine serum albumin, 0.02% Ficoll, 0.02% polyvinylpyrrolidone), 0.1% sodium dodecylsulfate (SDS), and 100 µg/ml salmon sperm DNA. Hybridization was performed overnight in a similar prehybridization solution with a [32P]deoxycytosine triphosphate ([32P]dCTP)- labeled 0.3-kb complementary DNA (cDNA) clone of human IL-8 mRNA (a kind gift from Dr. Ivan J. D. Lindley, Sandoz Forschungsinstitut, Austria), or a 0.4-kb 3' untranslated region (UTR) fragment of a human beta -actin cDNA clone.

The cDNAs were [32P]dCTP-labeled (Amersham) with a random-primer DNA labeling system (T7 QuickPrime Kit; Pharmacia LKB Biotechnology, Piscataway, NJ), and the oligonucleotide (for Southern blot analysis) was labeled by 5' end labeling. After hybridization, blots were washed twice at room temperature with solutions of increasing stringency (standard saline citrate with 0.1% SDS) and at increasing temperature until an adequate background reading was obtained. All filters were wrapped in plastic wrap and exposed to a phosphorimaging storage screen for 20 min before peak volume quantitation, which was done with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA), using ImageQuant software (33). Additionally, autoradiograms for IL-8 and beta -actin were generated by exposure of the filters to Kodak XAR-2 film (Eastman Kodak, Rochester, NY) at -80°C overnight.

Duplicate Hybond filters were hybridized with 32P-labeled IL-8 cDNA. After quantification with the PhosphorImager and autoradiography, the same filters were stripped and rehybridized with 32P-labeled human beta -actin cDNA. In order to normalize for loading quantities, the data were expressed as:
<FR><NU>IL-8 txt/IL-8 Co</NU><DE>β-actin txt/β-actin Co</DE></FR> (1)

which represents the ratio of IL-8-mRNA from treated cells (txt) to IL-8-mRNA from control cells (Co), divided by the ratio of beta -actin units of mRNA from treated cells to beta -actin units of mRNA from control cells.

Reverse Transcription-Polymerase Chain Reaction

Reverse transcription (RT) was done with Moloney murine leukemia virus reverse transcriptase, after which the polymerase chain reaction (PCR) was performed (34), with both procedures done according to the manufacturer's directions (Gibco/BRL, Life Technologies, Inc., Grand Island, NY), using a Perkin-Elmer (Norwalk, CT) PCR apparatus. In brief, the RT sample had a volume of 19.5 µl and the reaction was performed for 1 h at 37°C. Two microliters of reverse-transcribed product were used for the PCR (30 cycles) reaction of the pro-IL-1 sequence. From this PCR product, 2 µl were used for a nested PCR reaction of the secreted IL-1 sequence. A standardization protocol was implemented with beta -actin PCR as internal control. The primer used for the pro-IL-1beta upstream primer was 5'-GCCCTAAACAGATGAAGTGTCC-3', and that for the downstream primer was 5'-ATTGCATGGTGAAGTCAGTTATATC-3'. For the nested PCR of the secreted sequence of IL-1beta , a 5'-GCTGATGGCCCTAAACAG-3' upstream primer and 5'-GAAGACGGGCATGTTTTC-3' downstream primer were used. Primers for IL-1alpha were 5'-GTAAGCTATGGCCCACTC-3' and 5'-GAAATAGTTCTTAGTGCCGTG-3' (sense and antisense, respectively). RT-PCR analysis for pro-IL-1beta with subsequent nested PCR for the secreted sequence of IL-1beta was done with total RNA from uninfected A549 (control) and infected cells at 96 h of culture, together with U937 cells untreated and treated with PMA (10 ng/ml) for 24 h. An IL-1 cDNA was used as a positive control for the PCR.

Southern Blot Analysis

Agarose gel (1%) electrophoresis was done with 20 µl of the PCR product. An aliquot of DNA mass ladder (4 µl; Gibco/BRL, Life Technologies Inc., Gaithersburg, MD) was added for the recognition of bands.

The agarose gel was denatured by soaking it for 20 min in 0.4 N NaOH, 1 M NaCl, transferring the bands to nylon membranes (Hybond), and cross-linking. The Hybond membranes were prehybridized and hybridized according to the same used for the Northern blot analysis, with an IL-1beta oligonucleotide.

LacZ Staining of Cytospin Preparations

Cells were removed from the culture plates by trypsin digestion, washed with phosphate-buffered saline (PBS), and resuspended at a concentration of 25 × 105 cells/200 µl. Cytospin preparations were made on a cytocentrifuge (Shandon Southern, Sewickley, PA) at 700 rpm for 5 min, air dried for 1 h, and stored at -70°C until used. Slides were fixed with 0.5% glutaraldehyde for 10 min at room temperature, washed with PBS, and stained for 3 h with 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside (X-Gal) stain (5 mM potassium ferrous cyanide, 5 mM potassium ferric cyanide, 2 mM magnesium chloride, 1 mg/ml X-Gal, 0.02% NP40 in PBS). Av1LacZ4 expresses a nuclear-targeted LacZ gene. Therefore, A549 cells transduced by Av1LacZ4 have blue-staining nuclei after histochemical staining for beta -galactosidase.

Statistical Analysis

Statistical analysis, with replicate experiments as covariants (n = 3 experiments with three replicates), was done at each time point by analysis of variance, and subsequent analysis of mean pairs was done with Student's t test. Data are presented as means ± SD, and results were considered significant at P < 0.05.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

IL-8 Gene Expression in Infected Cells

Av1LacZ4 infection of the A549 epithelial monolayer at an MOI of 50 produced increased IL-8 gene expression. IL-8 gene expression, as measured from mRNA levels and compared with that in uninfected cells, was increased by 7.1 ± 6.2-fold at 24 h (P = 0.11), by 6.1 ± 4.4-fold at 48 h (P = 0.2), and by 9.3 ± 5.3-fold at 96 h (P < 0.06) (Figure 1). Stimulation of A549 cells with TNF-alpha at a concentration of 100 U/ml increased the IL-8 mRNA level by 24 h to 6.2-fold that of unstimulated cells, after which the levels decreased to near baseline by 96 h (data not shown).


View larger version (33K):
[in this window]
[in a new window]
 
Figure 1.   Northern blot analysis showing downregulation of IL-8 gene expression in infected A549 cells by pretreatment with 50 ng/ml IRAP. Cells were cultured as described in MATERIALS AND METHODS and were harvested at 24, 48, and 96 h after collection of supernatants. Human IL-8 cDNA hybridization blots are seen in upper row of autoradiograms, and human beta -actin cDNA hybridization blots are seen in lower row of autoradiograms. Bar graphs depict peak volume quantitation ratio of cytokine mRNA from treated cells to cytokine mRNA from control cells, divided by the ratio of beta -actin mRNA from treated cells to beta -actin mRNA from control cells (for normalization of loading) from three experiments (n = 3), with three replicates each. Peak volume quantitation was done with a PhosphorImager, using ImageQuant software. A significant statistical difference (asterisk) is seen at 96 h.

Demonstration of Extracellular IL-8

A549 cells constitutively produced low levels of IL-8. Infection of A549 cells with virus vector resulted in a significant increase in IL-8 secretion above baseline levels in a time-dependent fashion (Figure 2). At 24 h, the IL-8 level in the virus-infected group was 0.47 ± 0.08 ng/ml, whereas the level in the uninfected group was 0.17 ± 0.05 ng/ml (P < 0.001). At 48 h, the IL-8 level in the virus-infected group was 0.96 ± 0.18 ng/ml, whereas the level in the uninfected group was 0.46 ± 0.12 (P < 0.001), and by 96 h the levels in the two groups were 4.8 ± 0.22 ng/ml and 1.4 ± 0.09 ng/ml, respectively (P < 0.001) (Figure 2). The TNF-alpha - stimulated cells had a significantly greater concentration of IL-8 at all time points (7.1 ± 0.2 ng/ml at 24 h; 6.3 ± 0.3 ng/ml at 48 h; 7.9 ± 0.1 ng/ml at 96 h).


View larger version (27K):
[in this window]
[in a new window]
 
Figure 2.   ELISA results showing downregulation of IL-8 levels after infection by virus vector in A549 cells pretreated with 50 ng/ml IRAP. A significant statistical difference in vector-induced IL-8 levels as compared with the levels in control cells is seen at 24, 48, and 96 h. Significant downregulation of IL-8 production by pretreatment with IRAP is seen at 48 and 96 h (asterisks) in the vector infected cells as compared with the uninfected cells. Cells were cultured as described in MATERIALS AND METHODS and collection of supernatants was done at 24, 48, and 96 h. Bar graphs depict the average of IL-8 levels from three experiments (n = 3) with three replicates each.

Pretreatment of Virus Vector-Infected A549 Airway Epithelial Cells with IRAP

IRAP downregulated by one third the IL-8 gene activation induced by the virus vector, with the decrease reaching significance at 96 h (Figure 1). Protein levels of IL-8 were also significantly downregulated at both 48 and 96 h (P < 0.05) (Figure 2). In one experiment, IL-8 protein levels were standardized by cell counting, which showed consistency. IRAP did not affect IL-8 mRNA induced by TNF-alpha (data not shown), and IRAP alone did not have any affect on the constitutive production of IL-8.

Blocking Effect of IRAP on IL-8 Gene Activation in IL-1beta -Stimulated Respiratory Cells

IL-1beta could not be detected with ELISA in the supernatant from infected cells. To demonstrate that IL-1beta concentrations below the lower limit of the ELISA were able to induce mRNA and secretion of IL-8, we stimulated A549 cells with IL-1beta at concentrations of from 0.2 to 20 pg/ml. There was a dose-related increase in IL-8 expression with increasing concentrations of IL-1beta (Figure 3). A dose of IL-1beta as low as 0.2 pg/ml was able to induce a statistically significant increase in IL-8 concentration as compared with the concentration for unstimulated cells. Pretreatment of IL-1beta -stimulated cells with IRAP reduced IL-8 production in a dose-related manner (Figure 3).


View larger version (41K):
[in this window]
[in a new window]
 
Figure 3.   Downregulation of IL-8 by pretreatment with IRAP in IL-1beta -stimulated A549 cells. A significant dose-related increase is seen in IL-8 production with increasing concentrations of IL-1beta from 0.2 to 20 pg/ml (double asterisks; P < 0.02). This increase was downregulated by pretreatment with IRAP at a 50-fold excess over IL-1beta concentrations (asterisk; P < 0.03). Cells were cultured as described in MATERIALS AND METHODS, and collection of supernatants was done at 24 h. Bar graphs depict the average of IL-8 levels from two experiments (n = 2) with three replicates each.

RT-PCR and Southern Blot Hybridization for IL-1beta from Infected Cells

The expected 713-bp size band for pro-IL-1beta was identified, and a 404-bp band was identified for the IL-1beta cDNA after the nested PCR (Figure 4). We found increased (and sustained) expression of IL-1beta mRNA in the infected cells as compared with the untreated uninfected cells. Recognition of bands for IL-1beta (pro- and cDNA) was done through Southern blot analysis with a 300-bp cDNA for IL-1beta (Figure 5). No bands were seen after RT-PCR analysis done with primers for IL-1alpha .


View larger version (33K):
[in this window]
[in a new window]
 
Figure 4.   RT-PCR gel showing a 713-bp DNA band representing the pro-IL-1beta band for infected A549 cells as well as U937 cells untreated and treated with PMA for 24 h (as positive control). There was no band for uninfected (control) A549 cells. Agarose gel electrophoresis with ethidium bromide staining shows RT-PCR results with pro-IL-1beta primers, as described in MATERIALS AND METHODS (asterisk: DNA mass ladder recognizing fragments of 2,000, 1,200, 800, 400, and 200 bp).


View larger version (34K):
[in this window]
[in a new window]
 
Figure 5.   Autoradiograms of Southern blots of nested PCR products, showing homologous recognition of pro-IL-1beta (713 bp) and secreted IL-1beta (300 bp) bands. Bands are seen for virus vector-infected A549 cells and U937 cells, untreated and treated with PMA. No band is seen for uninfected (control) A549 cells. Hybridization of the nested PCR products was done on nylon membranes, using an IL-1 beta  oligonucleotide, as described in MATERIALS AND METHODS.

Determination of IL-1beta Production by ELISA of Concentrated Supernatants and Membrane Preparations

We were unable to detect IL-1beta in unconcentrated supernatants. The concentrated supernatants from vector-infected cells showed significantly higher levels of IL-1beta at 96 h (37 ± 1 pg/ml) than did concentrated supernatants from uninfected control cells, in which IL-1beta was undetectable.

Av1LacZ4 Transduction Rate

The rate of transduction of A549 cells with Av1LacZ4 at 24, 48, and 96 h after exposure to the virus was 47.5 ± 15.6%, 80 ± 5.09%, and 85.5 ± 3.93%, respectively, indicating efficient transduction by the virus.

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The results of this study support the hypothesis that the adenovirus vector Av1LacZ4 partly induces IL-8 transcription and secretion in A549 cells through IL-1beta induction. By blocking the IL-1 receptor with IRAP and partly inhibiting the adenovirus vector-induced expression and release of IL-8, we showed the relationship of IL-1 to IL-8 induction. Other researchers have showed a mechanism of IL-8 production through primary IL-1 induction. Lukacs and colleagues (34) demonstrated significantly decreased levels of IL-8 on Day 5 of culture after IRAP pretreatment at 25 ng/ml. DeForge and coworkers (26) addressed the question of whether IRAP would suppress IL-8 produced by LPS-stimulated human blood monocytes, and found downregulation of IL-8 by IRAP. Kaplanski and associates (27) verified a similar mechanism of IL-8 production through IL-1 in activated platelets, and Porat and coworkers (34) showed that Borrelia burgdorferi induces IL-8 by IL-1 induction, which can be regulated by IRAP.

We were able to demonstrate expression and secretion of IL-1beta by virus-infected cells through RT-PCR, and to measure secreted IL-1beta protein in concentrated supernatants from treated cells, although we failed to detect IL-1beta in the supernatants of infected cell with the usual ELISA technique. Smith and colleagues (35) have also reported IL-1beta production by A549 cells. We showed that a concentration below 15 pg/ml of IL-1beta in the supernatant was sufficient to induce IL-8 production, and that the resulting IL-8 levels could be reduced by pretreating the cells with IRAP. Furthermore, we found that the adenovirus vector used in our study induced sustained expression of IL-1beta and IL-8 for up to 96 h, which contrasts markedly with the peak of cytokine activity occurring at 24-48 h when A549 cells were stimulated with IL-1beta or TNF-alpha . RT-PCR analysis for IL-1beta mRNA and ELISA measurements of concentrated supernatants for secreted IL-1beta polypeptide showed that this cytokine was present for up to 96 h after infection of A549 cells, whereas no mRNA or antigenic protein was found in untreated cells. The viral effect on IL-1beta induction in cells infected in vitro is consistent with the finding in previous studies that showed a direct stimulation of IL-1alpha and IL-1beta production by other viruses, such as CMV and RSV (21, 36, 37).

The immune response to wild type adenovirus is modulated by several viral gene products (13). It is not clear how the virus stimulates the induction of IL-1. IL-1, TNF, and PMA induce IL-8 by inducing a nuclear factor (NF)- kappa B-like factor that complexes the region between -80 and -71 bp of the IL-8 promoter (38). Another factor, binding to the region between -94 and -81 bp, and which was proposed (39) as a pathway for cooperative IL-1 gene expression by IL-1, TNF, or PMA, is an NF-IL-6-like factor coupled to CCAAT/enhancer binding protein (C/EBP). The IL-6 gene is inducible by IL-1 or TNF (13). IL-1 induces translocation of the NF-kappa B-like factor, replacing the weaker C/EBP-like factor and leading to expression of IL-8.

Our current study provides an important contribution to the understanding of viral induction of IL-8 by demonstrating IL-1 activation (which activates translocation of the NF-kappa b-like factor [39] and leads to IL-8 gene expression). IRAP could be effective in the treatment of patients with viral infections when IL-8 induction is the main pathway inducing inflammation. Specifically, IRAP can be given prophylactically to patients undergoing gene therapy in order to prevent the activation of IL-8 as well as other effects of IL-1. McCoy and associates (40) were unable to show blockage of inflammation induced by the virus vector AdRSV, which contained a human cDNA IRAP. We performed a 90-min preincubation of A549 cells with IRAP before infection or IL-1 stimulation. Moreover, we used IRAP in a 50-fold excess over IL-1beta concentrations, owing to the potent inflammatory effect of low concentrations of IL-1 (0.2 pg/ml). The peak levels of expression of IRAP in McCoy and colleagues' study were 5.5 ng/ml in the BALF of male CBA/J mice, but they did not measure the level of IL-1beta in the fluid. To be able to block the proinflammatory effects of IL-1beta , IRAP has to be present in a sufficient excess (41, 42). It can be hypothesized that if McCoy and colleagues' mice had been pretreated with IRAP or actually inoculated with virus having a promoter that amplifies the transcription of human IRAP in order to induce enough copies of the IRAP protein, it would have been present in a sufficient excess to block IL-1.

Other models of induction of IL-8 could be studied by using IRAP to block IL-8 production and demonstrate that such production occurs through IL-1 activation. Such models would be useful for studying mechanisms of inflammation in different diseases in which IL-8 is expressed.

In summary, our study contributes to the understanding and modulation of virus-induced inflammation by suggesting a role for IL-1 in early induction of the cytokine network that leads to airway inflammation after the administration of adenoviral vectors.

    Footnotes

Abbreviations: complementary DNA, cDNA; cystic fibrosis transmembrane regulator, CFTR; interleukin, IL; interleukin-1 receptor antagonist, IRAP; polymerase chain reaction, PCR; reverse transcription-polymerase chain reaction, RT-PCR.

(Received in original form September 10, 1998 and in revised form February 25, 1999).

Acknowledgments: This study was supported by grant 51832 from the National Heart, Lung, and Blood Institute, the Center for Gene Therapy for Cystic Fibrosis, and the Cystic Fibrosis Foundation.
    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Boat, T. F, M. J. Welsh, and A. L. Beaudet. 1989. Cystic fibrosis. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 2649-2680.

2. Kerem, B., J. M. Rommens, J. A. Buchanan, D. Markiewicz, T. K. Cox, A. Chakravarti, M. Buchwald, and L. C. Tsui. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073-1080 [Abstract/Free Full Text].

3. Rommens, J. M., M. C. Iannuzzi, B. Kerem, M. L. Drumm, G. Melmer, M. Dean, R. Rozmahel, J. L. Cole, D. Kennedy, and N. Hidaka. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245: 1059-1065 [Abstract/Free Full Text].

4. Riordan, J. R., J. M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, and J. L. Chou. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073. (Published erratum appears in Science 1989;245:1437).

5. Bear, C. E., C. H. Li, N. Kartner, R. J. Bridges, T. J. Jensen, M. Ramjeesingh, and J. R. Riordan. 1992. Purification and functional reconstruction of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68: 809-818 [Medline].

6. Tsui, L.C., J. Rommens, B. Kerem, R. Rozmahel, J. Zielenski, D. Kennedy, D. Markiewicz, N. Plavsic, J. L. Chou, and D. Bozon. 1991. Molecular genetics of cystic fibrosis. Adv. Exp. Med. Biol. 290: 9-17 [Medline].

7. Wilmott, R. W., J. A. Whitsett, and B. C. Trapnell. 1993. Gene therapy of cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane regulator cDNA to the airways. A phase I study. 1994  Hum. Gene Ther. 5: 1019 .

8. Trapnell, B. C.. 1993. Adenoviral vectors for gene transfer. Advanced Drug Delivery Rev. 12: 185-199 .

9. Rosenfeld, M. A., K. Yoshimura, B. C. Trapnell, K. Yoneyama K, E. R. Rosenthal, W. Dalemans, M. Fukayama, J. Bargon, L. E. Stier, and L. Stratford-Perricaudet. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155.

10. Welsh, M. J., Principal investigator. 1992. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in the nasal epithelium. Fed. Regist. (57 FR 49584).

11. Wilson, J. M., Principal investigator. 1992. Gene therapy of cystic fibrosis lung diseases using E1-deleted adenovirus: a phase 1 trial. Fed. Regist. (57 FR 49584).

12. Rich, D. P., L. A. Couture, L. M. Cardoza, V. M. Guiggio, D. Armentano, P. C. Espino, K. Hehir, M. J. Welsh, A. E. Smith, and R. J. Gregory. 1993. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther. 4: 461-476 [Medline].

13. Wadell, G. 1994. Adenoviruses. In The Encyclopedia of Virology. R. G. Webster and A. Granoff, editors. Academic Press, San Diego, CA.

14. Brody, S. L., M. Metzger, C. Danel, M. A. Rosenfeld, and R. G. Crystal. 1994. Acute response of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5: 821-836 [Medline].

15. Wilmott, R. W., R. S. Amin, C. R. Perez, S. E. Wert, G. Keller, G. P. Boivin, R. Hirsch, J. Inocencio, P. Lu, S. F. Reising, S. Yei, J. A. Whitsett, and B. C. Trapnell. 1996. Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of non-human primates. Hum. Gene Ther. 7: 301-318 [Medline].

16. Simon, R. H., J. F. Engelhardt, Y. Yang, M. Zepeda, S. W. Pendleton, M. Grossman, and J. M. Wilson. 1993. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: toxicity study. Hum. Gene Ther. 4: 771-780 [Medline].

17. Brody, S. L., M. E. Metzger, and R. G. Crystal. 1993. Repeat airway administration of replication deficient recombinant adenovirus vectors to non-human primates is safe and effective. Am. Rev. Respir. Dis. 147: A544 .

18. Yei, S., N. Mittereder, S. Wert, J. A. Whitsett, R. W. Wilmott, and B. C. Trapnell. 1994. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum. Gene Ther. 5: 731-744 [Medline].

19. Amin, R. S., R. Wilmott, Y. Schwarz, B. Trapnell, and J. Stark. 1995. Replication-deficient adenovirus induces expression of Interleukin-8 by airway epithelial cells in vitro. Hum. Gene Ther. 6: 145-153 [Medline].

20. Standiford, T. J., S. L. Kunkel, M. A. Basha, S. W. Chensue, J. P. Lynch, G. B. Toews, J. Westwick, and R. M. Strieter. 1990. Interleukin-8 gene expression by a pulmonary epithelial cell line: a model for cytokine networks in the lung. J. Clin. Invest. 86: 1945-1953 .

21. Dudding, L., S. Haskill, B. D. Clark, P. E. Auron, S. Sporn, and E. S. Huanf. 1989. Cytomegalovirus infection stimulates expression of monocyte-associated mediator genes. J. Immunol. 143: 3343-3352 [Abstract].

22. Panuska, J. R., M. I. Hertz, H. Taraf, A. Villani, and N. M. Cirino. 1992. Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients. Am. Rev. Respir. Dis. 145: 934-939 [Medline].

23. Becker, S., J. Quay, and J. Soukup. 1991. Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J. Immunol. 147: 4307-4312 [Abstract].

24. Becker, S., H. S. Koren, and D. C. Henke. 1993. Interleukin-8 expression in normal nasal epithelium and its modulation by infection with respiratory syncytial virus and cytokines tumor necrosis factor, interleukin-1, and interleukin-6. Am. J. Respir. Cell Mol. Biol. 8: 20-27 .

25. Lukacs, N. W., S. L. Kunkel, M. D. Burdick, P. M. Lincoln, and R. M. Strieter. 1993. Interleukin-1 receptor antagonist blocks chemokine production in the mixed lymphocyte reaction. Blood 82: 3668-3674 [Abstract/Free Full Text].

26. DeForge, L. E., D. E. Tracey, J. S. Kenney, and D. G. Remick. 1992. Interleukin-1 receptor antagonist protein inhibits interleukin-8 expression in lipopolysaccharide-stimulated human whole blood. Am. J. Pathol. 140: 1045-1054 [Abstract].

27. Kaplanski, G., R. Porat, K. Aiura, J. K. Erban, J. A. Gelfand, and C. A. Dinarello. 1993. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 81: 2492-2495 [Abstract/Free Full Text].

28. Hornbeck, P. 1993. Enzyme-linked immunosorbent assay. In Current Protocols in Immunology. F. Ausubel et al., editors. Wiley-Greene, New York. 11.3.1.

29. Weissman, A. M. 1991. Solubilization of cellular proteins. In Current Protocols in Immunology. J. E. Cologan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, editors. National Cancer Institute. National Institutes of Health, Bethesda, MD. Section I, Unit 8.1:811-819.

30. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159 [Medline].

31. Hames, B. D., and S. J. Higgins. 1985. Nucleic acid hybridisation, a practical approach. In The Practical Approach, Series 14. D. Rickwood and B. D. Hames, editors. IRL Press, Washington DC. 90.

32. Johnston, R. F., S. C. Pickett, and D. L. Barker. 1990. Autoradiography using storage phosphor technology. Electrophoresis 11: 355-360 [Medline].

33. Kawasaki, E. S. 1990. Amplification of rank. In PCR Protocols: A Guide to Methods and Applications. M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White, editors. Academic Press, San Diego, CA. 21.

34. Porat, R., D. D. Poutsiaka, L. C. Miller, E. V. Granowitz, and C. A. Dinarello. 1992. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J. 6: 2482-2486 [Abstract].

35. Smith, D. R., S. L. Kunkel, T. J. Standiford, S. W. Chensue, M. W. Rolfe, M. B. Orringer, R. I. Whyte, M. D. Burdick, J. M. Danforth, A. R. Gilbert, and R. M. Strieter. 1993. The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. Am. J. Pathol. 143: 794-803 [Abstract].

36. Lewis, M. A., J. S. Slater, L. I. Leverone, and A. E. Campbell. 1990. Enhancement of interleukin-1 activity by murine cytomegalovirus infection of a macrophage cell line. Virology 178: 452-460 [Medline].

37. Patel, J. A., M. Kunimoto, T. C. Sim, R. Garofalo, T. Eliott, S. Baron, O. Ruuskanen, T. Chonmaitree, P. L. Ogra, and F. Schmalstieg. 1995. Interleukin-1alpha mediates the enhanced expression of intracellular adhesion molecule-1 in pulmonary epithelial cells infected with respiratory syncytial virus. Am. J. Respir. Cell Mol. Biol. 16: 602-609 .

38. Mukaida, N., Y. Mache, and K. Matsushima. 1990. Cooperative interaction of NF-kappa B- and C/EBP-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J. Biol. Chem. 265: 21128-21133 [Abstract/Free Full Text].

39. Shimizu, H., K. Mitomo, T. Watanabe, S. Okamoto, and K. Yamamoto. 1990. Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol. Cell. Biol. 10: 561-568 [Abstract/Free Full Text].

40. McCoy, R. D., B. L. Davidson, B. J. Roessler, G. B. Huffnagle, and R. H. Simon. 1995. Expression of human interleukin-1 receptor antagonist in mouse lungs using a recombinant adenovirus: effects on vector-induced inflammation. Gene Ther. 7: 437-442 .

41. Arend, O. W. P., H. G. Welgus, H. G. Thompson, and S. P. Eisenberg. 1990. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85: 1694-1697 .

42. Kent, S., R. M. Bluthe, R. Dantzer, A. J. Hardwick, and K. W. Kelley. 1992. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc. Natl. Acad. Sci. USA. 89:19, 9117-9120.





This article has been cited by other articles:


Home page
Infect. Immun.Home page
K. Chakrabarty, W. Wu, J. L. Booth, E. S. Duggan, N. N. Nagle, K. M. Coggeshall, and J. P. Metcalf
Human Lung Innate Immune Response to Bacillus anthracis Spore Infection
Infect. Immun., August 1, 2007; 75(8): 3729 - 3738.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
D. J. Wallace, M. Linker-Israeli, D. Hallegua, S. Silverman, D. Silver, and M. H. Weisman
Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study
Rheumatology, July 1, 2001; 40(7): 743 - 749.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwarz, Y. A.
Right arrow Articles by Wilmott, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwarz, Y. A.
Right arrow Articles by Wilmott, R. W.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 1999 American Thoracic Society.